MTEP
Prijeđi na navigaciju
Prijeđi na pretragu
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| 3-[(2-metil-1,3-tiazol-4-il)etinil]piridin | |||
| Klinički podaci | |||
| Identifikatori | |||
| CAS broj | 329205-68-7 | ||
| ATC kod | nije dodeljen | ||
| PubChem[1][2] | 9794218 | ||
| Hemijski podaci | |||
| Formula | C11H8N2S | ||
| Mol. masa | 200,260 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | |||
3-[(2-Metil-4-tiazolil)etinil]piridin (MTEP) je lek koji se koristi u naučnim istraživanjima. Razvila ga je kompanija Merck & Co.. On je selektivan alosteran antagonist metabotropnog glutamatnog receptora mGluR5. On je identifikovan putem studija odnosa strukture i aktivnosti starijeg mGluR5 antagonista MPEP.[3] MTEP je naknadno korišten kao vodeće jedinjenje za novije i potentnije lekiva.[4][5]
Reference[uredi | uredi kod]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Cosford ND, Tehrani L, Roppe J, et al. (January 2003). „3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity”. J. Med. Chem. 46 (2): 204–6. DOI:10.1021/jm025570j. PMID 12519057.
- ↑ Iso Y, Grajkowska E, Wroblewski JT, et al. (February 2006). „Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications”. J. Med. Chem. 49 (3): 1080–100. DOI:10.1021/jm050570f. PMID 16451073.
- ↑ Kulkarni SS, Newman AH (June 2007). „Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists”. Bioorg. Med. Chem. Lett. 17 (11): 2987–91. DOI:10.1016/j.bmcl.2007.03.066. PMC 1973162. PMID 17446071.
